Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar;33(2):256-276.
doi: 10.3904/kjim.2018.036. Epub 2018 Feb 27.

Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea

Sung-Yeon Cho  1   2   3 , Hyeon-Jeong Lee  1 , Dong-Gun Lee  1   2   3
Affiliations
Review

Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea

Sung-Yeon Cho et al. Korean J Intern Med. 2018 Mar.

Abstract

Hematopoietic stem cell transplantation (HSCT) is a treatment for hematologic malignancies, immune deficiencies, or genetic diseases, ect. Recently, the number of HSCTs performed in Korea has increased and the outcomes have improved. However, infectious complications account for most of the morbidity and mortality after HSCT. Post-HSCT infectious complications are usually classified according to the time after HSCT: pre-engraftment, immediate post-engraftment, and late post-engraftment period. In addition, the types and risk factors of infectious complications differ according to the stem cell source, donor type, conditioning intensity, region, prophylaxis strategy, and comorbidities, such as graft-versushost disease and invasive fungal infection. In this review, we summarize infectious complications after HSCT, focusing on the Korean perspectives.

Keywords: Hematopoietic stem cell transplantation; Immunocompromised host; Infectious diseases; Opportunistic infections.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Figure 1.
Figure 1.
Cumulative incidence of herpes zoster in allogeneic hematopoietic stem cell transplantation with myeloablative (MAC) or reduced intensity conditioning (RIC) regimens without long-term prophylaxis (log-rank test, p = 0.492).
Figure 2.
Figure 2.
Cumulative incidence of tuberculosis (TB) in allogeneic hematopoietic stem cell transplantation (HSCT) recipients with and without chronic graft-versus-host disease (cGVHD) (p = 0.003).
See this image and copyright information in PMC

References

    1. Lee DG. Common infectious diseases in hematopoietic stem cell transplant recipients. Korean J Med. 2013;84:158–167.
    1. Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Hematol Oncol Clin North Am. 2011;25:101–116. - PubMed
    1. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15:1143–1238. - PMC - PubMed
    1. Safdar A, Armstrong D. Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects. Clin Infect Dis. 2011;53:798–806. - PubMed
    1. Lee JW, Kim CC. The activity of hematopoietic stem cell transplantation in Korea. Bone Marrow Transplant. 2008;42 Suppl 1:S92–S95. - PubMed

MeSH terms

LinkOut - more resources